Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group

doi:10.1016/j.ophtha.2019.11.004

Ophthalmology

Volume 127, Issue 5, May 2020, Pages 616-636

, , , , , , , , , , , , , , , , , , , …

https://doi.org/10.1016/j.ophtha.2019.11.004 Get rights and content

Under a Creative Commons license

open access

Purpose

To establish a process to evaluate and standardize a state-of-the-art nomenclature for reporting neovascular age-related macular degeneration (AMD) data.

Design

Consensus meeting.

Participants

An international panel of retina specialists, imaging and image reading center experts, and ocular pathologists.

Methods

During several meetings organized under the auspices of the Macula Society, an international study group discussed and codified a set nomenclature framework for classifying the subtypes of neovascular AMD and associated lesion components.

Main Outcome Measures

A consensus classification of neovascular AMD.

Results

The study group created a standardized working definition of AMD. The components of neovascular AMD were defined and subclassified. Disease consequences of macular neovascularization were delineated.

Conclusions

The framework of a consensus nomenclature system, a definition of AMD, and a delineation of the subtypes of neovascular AMD were developed. Establishing a uniform set of definitions will facilitate comparison of diverse patient groups and different studies. The framework presented is modified and updated readily, processes that are anticipated to occur on a periodic basis. The study group suggests that the consensus standards outlined in this article be used in future reported studies of neovascular AMD and clinical practice.

Abbreviations and Acronyms

AMD

age-related macular degeneration

CONAN

Consensus on Neovascular AMD Nomenclature

cORA

complete outer retinal atrophy

MNV

macular neovascularization

PED

pigment epithelial detachment

RPE

retinal pigment epithelium

SHRM

subretinal hyperreflective exudative material

VEGF

vascular endothelial growth factor

Cited by (0)

: Financial Disclosure(s): The author(s) have made the following disclosure(s): R.F.S.: Consultant – Topcon Medical Systems, Roche, Genentech; Royalties – Topcon Medical Systems, DORC.

: G.J.J.: Heidelberg Engineering, Novartis, Roche.

: D.S.: Consultant – Amgen, Bayer, Genentech, Novartis, Optovue; Financial support – Genentech, Regeneron.

: K.B.F.: Consultant – Novartis, Allergan, Zeiss, Optovue, Heidelberg Engineering; Financial support – Genentech/Roche.

: S.R.S.: Consultant – Amgen, Allergan, Bayer, Novartis, Genentech/Roche, Oxurion, Heidelberg Engineering, Optos, Carl Zeiss Meditec, Centervue; Financial support – Carl Zeiss Meditec; Nonfinancial support – Nidek, Topcon.

: G.S.: Consultant – Heidelberg Engineering, Nidek, Centervue; Financial support – Heidelberg Engineering, Carl Zeiss Meditec, Optovue, Nidek, Centervue, Topcon.

: N.K.W.: Consultant – Optovue, Topcon; Nonfinancial support – Optovue, Carl Zeiss Meditec, Nidek.

: P.J.R.: Consultant and Financial support – Carl Zeiss Meditec.

: F.G.H.: Consulting fees – Heidelberg Engineering, Carl Zeiss Meditec, Bayer, Novartis, Genentech/Roche, Acucela, Apellis, Allergan, Pixium, Kodiak, Lin Bioscience; Financial support – Heidelberg Engineering, Carl Zeiss Meditec, Centervue, Bayer, Novartis, Genentech/Roche, Acucela, Apellis.

: E.H.S.: Consultant – Allergan, Bayer, Novartis, Roche.

: S.Y.C.: Consultant – Allergan, Bayer, Novartis, Roche, Thea, Tilak.

: G.Q.: Consultant – Alimera, Allergan, Bayer, Lumithera, KBH, Novartis, Roche, Sandoz, Sifi, Zeiss, Topcon, Thea, Heidelberg, Fidia-Sooft, Bausch & Lomb.

: D.B.: Consultant – Alcon, Genentech, Regeneron, Allergan, Novartis, Oxurion.

: A.G.: Consultant – Novartis, Thrombogenics; Nonfinancial support – Bayer.

: C.R.B.: Consultant – Genentech, Novartis.

: S.S-V.: Financial support – Accucela, Allergan, Bayer, Bioeq/Formycon, Centervue, Genentech/Roche, Katairo, Novartis; Consultant – Allergan, Bayer, Bioeq/Formycon, Carl Zeiss MediTec AG, Galimedix, Genentech/Roche, Novartis, Heidelberg Engineering.

: U.S-E.: Consultant – Boehringer Ingelheim, Genentech, Novartis, Roche.

: R.G.: Consultant – Novartis, Bayer, Apellis, Roche/Genentech.

: K.C.: Consultant – Ophthotech, Allergan, Regeneron, Roche, Heidelberg Engineering, Novartis, Genentech; Financial support – Ophthotech.

: J.M.M.: Consultant – Novartis, Roche, Cellcure, Kodiak, Notalvision, Reneuron; Financial support – Novartis, Roche, Bayer, Ophthotech, Reneuron, Apellis, Thrombogenics, Kodiak; Equity owner – Ophthotech, Notalvision.

: R.T.: Consultant – Allergan, Novartis, Bayer, Genentech, Roche, Oculis, Alcon; Financial support – Novartis, Bayer, Allergan, Alcon; Nonfinancial support – Zeiss, Moria.

: J.F.: Consultant – Topcon; Royalties – Optovue.

: Supported in part by the Macula Society, Cleveland, OH; Heidelberg Engineering, Inc; Optovue Inc, Topcon Medical Systems, Inc, and Zeiss-Meditec, Inc. The sponsors had no role in the design or conduct of this research and no input in writing the article.

: HUMAN SUBJECTS: No human subjects were included in this study.

: No animal subjects were included in this study.

: Author Contributions:

: Conception and design: Spaide, Jaffe, Sarraf, Freund, Sadda, Staurenghi, Waheed, Chakravarthy, Rosenfeld, Holz, Souied, Cohen, Querques, Ohno-Matsui, Boyer, Gaudric, Blodi, Baumal, Li, Coscas, Brucker, Singerman, Luthert, Schmitz-Valckenberg, Schmidt-Erfurth, Grossniklaus, Wilson, Guymer, Yannuzzi, Chew, Csaky, Monés, Pauleikhoff, Tadayoni, Fujimoto

: Analysis and interpretation: Spaide, Jaffe, Sarraf, Freund, Sadda, Staurenghi, Waheed, Chakravarthy, Rosenfeld, Holz, Souied, Cohen, Querques, Ohno-Matsui, Boyer, Gaudric, Blodi, Baumal, Li, Coscas, Brucker, Singerman, Luthert, Schmitz-Valckenberg, Schmidt-Erfurth, Grossniklaus, Wilson, Guymer, Yannuzzi, Chew, Csaky, Monés, Pauleikhoff, Tadayoni, Fujimoto

: Data collection: Spaide, Jaffe, Sarraf, Freund, Sadda, Staurenghi, Waheed, Chakravarthy, Rosenfeld, Holz, Souied, Cohen, Querques, Ohno-Matsui, Boyer, Gaudric, Blodi, Baumal, Li, Coscas, Brucker, Singerman, Luthert, Schmitz-Valckenberg, Schmidt-Erfurth, Grossniklaus, Wilson, Guymer, Yannuzzi, Chew, Csaky, Monés, Pauleikhoff, Tadayoni, Fujimoto

: Obtained funding: Spaide, Jaffe, Sarraf, Freund, Sadda, Staurenghi, Waheed, Chakravarthy, Rosenfeld, Holz, Souied, Cohen, Querques, Ohno-Matsui, Boyer, Gaudric, Blodi, Baumal, Li, Coscas, Brucker, Singerman, Luthert, Schmitz-Valckenberg, Schmidt-Erfurth, Grossniklaus, Wilson, Guymer, Yannuzzi, Chew, Csaky, Monés, Pauleikhoff, Tadayoni, Fujimoto

: Overall responsibility: Spaide, Jaffe, Sarraf, Freund, Sadda, Staurenghi, Waheed, Chakravarthy, Rosenfeld, Holz, Souied, Cohen, Querques, Ohno-Matsui, Boyer, Gaudric, Blodi, Baumal, Li, Coscas, Brucker, Singerman, Luthert, Schmitz-Valckenberg, Schmidt-Erfurth, Grossniklaus, Wilson, Guymer, Yannuzzi, Chew, Csaky, Monés, Pauleikhoff, Tadayoni, Fujimoto

© 2019 by the American Academy of OphthalmologyThis is an open access article under the CC BY-NC-ND license (<inter-ref xlink: href=http://creativecommons.org/licenses/by-nc-nd/4.0/>http://creativecommons.org/licenses/by-nc-nd/4.0/</inter-ref>).